Roche nabs breakthrough tag for TIGIT cancer immunotherapy
Roche nabs breakthrough tag for TIGIT cancer immunotherapy Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack […]
Read More